Marshall Wace LLP acquired a new stake in Savara Inc (NASDAQ:SVRA - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 361,229 shares of the company's stock, valued at approximately $1,109,000. Marshall Wace LLP owned approximately 0.21% of Savara at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of SVRA. Cibc World Markets Corp purchased a new position in shares of Savara in the fourth quarter valued at $33,000. XTX Topco Ltd bought a new position in Savara in the 4th quarter worth about $34,000. KLP Kapitalforvaltning AS bought a new position in Savara in the 4th quarter worth about $41,000. Virtu Financial LLC purchased a new position in Savara during the 3rd quarter valued at about $67,000. Finally, Jump Financial LLC bought a new stake in shares of Savara during the fourth quarter valued at about $64,000. Institutional investors own 87.93% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright restated a "buy" rating and set a $6.00 price target on shares of Savara in a research report on Friday, March 28th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $8.83.
Check Out Our Latest Research Report on SVRA
Savara Price Performance
Shares of SVRA traded up $0.02 during midday trading on Monday, reaching $3.42. The stock had a trading volume of 172,708 shares, compared to its average volume of 1,295,235. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $589.93 million, a price-to-earnings ratio of -7.97 and a beta of 0.44. The company's 50-day moving average is $2.83 and its 200 day moving average is $3.05. Savara Inc has a 12-month low of $2.26 and a 12-month high of $5.31.
Savara (NASDAQ:SVRA - Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The business had revenue of $0.27 million during the quarter. On average, equities analysts predict that Savara Inc will post -0.45 EPS for the current fiscal year.
Savara Company Profile
(
Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Further Reading
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
